0000000000367138

AUTHOR

Karla Geiss

showing 5 related works from this author

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries

2016

AbstractWe aimed at investigating the distribution and risk of second primary cancers (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding of SPCs and insight into their incidence rates and recording practices. MM patients diagnosed in 1997–2010 at age ≥15 years were selected from the Swedish (nationwide) and 12 German cancer registries. Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compared to risk of the same first cancer in the corresponding background population. Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs were recorded, respectively. Significantly elevated S…

AdultMale0301 basic medicineOncologyPediatricsmedicine.medical_specialtyTime FactorsMyeloidAdolescentNervous System NeoplasmsPopulationAntineoplastic AgentsArticle03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicinemedicineHumansRegistriesSurvivorseducationMultiple myelomaAgedSwedeneducation.field_of_studyMultidisciplinarybusiness.industryIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseKidney NeoplasmsLeukemia Myeloid AcuteLeukemiaEarly Diagnosis030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisEpidemiology ; Cancer epidemiology ; MyelomaEtiologyFemaleMultiple MyelomabusinessKidney cancerScientific Reports
researchProduct

Response: Methods for second primary cancers evaluation have to be standardized

2017

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryIncidence (epidemiology)Endometrial cancerCancerSecond primary cancermedicine.diseaseSecond Primary CancersCancer registry03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineEpidemiology of cancermedicineEtiologybusinessInternational Journal of Cancer
researchProduct

Survival for patients with rare haematologic malignancies: Changes in the early 21st century

2017

Abstract Introduction Population-level survival has improved for common haematologic malignancies in the early 21st century. However, relatively few population-level data are available for rare haematologic malignancies. Methods Data were extracted from 12 cancer registries in Germany and the Surveillance, Epidemiology and End Results database in the United States (US). Cases of haematologic malignancies with an incidence of less than 1 per 100,000 were selected for analysis. Period analysis was used to determine 5-year relative survival (RS) for the years 2003–2012, and modelled period analysis was used to determine changes in survival between 2003–2007 and 2008–2012. Results Seven individ…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyPathologyTime FactorsAdolescentAnaplastic LymphomaYoung Adult03 medical and health sciencesRare Diseases0302 clinical medicineGermanyInternal medicineHumansMedicineRegistriesHealthcare DisparitiesYoung adultSurvival analysisAgedMycosis fungoidesRelative survivalbusiness.industryIncidenceIncidence (epidemiology)CancerMiddle Agedmedicine.diseaseSurvival AnalysisUnited StatesTreatment OutcomeOncologyHematologic Neoplasms030220 oncology & carcinogenesisFemaleMantle cell lymphomabusinessSEER Program030215 immunologyEuropean Journal of Cancer
researchProduct

Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries

2015

We aimed at investigating the distribution and risk of all second discordant primary cancers (SDPCs) after a specific first primary cancer in Germany and Sweden to provide etiological understanding of SDPCs and insight into their incidence rates and recording practices. Among 1,537,004 survivors of first primary cancers in Germany and 588,103 in Sweden, overall 80,162 and 32,544 SDPCs were recorded, respectively. Standardized incidence ratios (SIRs) of all SDPCs were elevated at levels between 1.1 and 2.1 after 23 (out of overall 29) cancers in Germany and at levels between 1.1 and 1.6 after 24 cancers in Sweden, and among them, elevated SIRs were found after 19 cancers in both populations.…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyPediatricsPoor prognosisAdolescentDisease-Free SurvivalYoung AdultRisk FactorsGermanyInternal medicinemedicineHumansRegistriesAge of OnsetYoung adultAgedAged 80 and overSwedenbusiness.industryIncidenceIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle AgedPrimary cancermedicine.diseasehumanitiesCancer registryOncologyEtiologyFemaleAge of onsetbusinessCancer Letters
researchProduct

Risk of second primary cancers in women diagnosed with endometrial cancer in G erman and S wedish cancer registries

2017

Along with the increasing incidence and favorable prognosis, more women diagnosed with endometrial cancer may develop second primary cancers (SPCs). We aimed at investigating risk of SPCs after endometrial cancer in Germany and Sweden to provide insight into prevention strategies for SPCs. Endometrial cancer patients diagnosed at age ≥15 years in Germany during 1997-2011 and in Sweden nationwide during 1997-2012 were selected. Standardized incidence ratios (SIRs), calculated as the ratio of observed to expected numbers of cases, were used to assess the risk of a specific second cancer after endometrial cancer for both German and Swedish datasets. Among 46,929 endometrial cancer survivors in…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAdolescentYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicineEpidemiology of cancermedicineHumansRegistriesYoung adultAgedAged 80 and overSwedenGynecologyCancer preventionbusiness.industryIncidenceEndometrial cancerIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseEndometrial NeoplasmsCancer registry030104 developmental biologyOncology030220 oncology & carcinogenesisFemalebusinessKidney cancerInternational Journal of Cancer
researchProduct